REACX Trademark
Serial Number: 97694234
Trademark Classes
Owner Contact Info
Legal Representation
Correspondence Address
Katharyn Bond KAT BOND LAW
21C ORINDA WAY, NO. 1721
ORINDA, CA 94563
United States
Trademark Details
Filing Date
November 28, 2022
Registration Date
Not Registered
Published for Opposition
January 2, 2024
Goods & Services
Pharmaceutical preparations for the treatment of addiction to and abuse of alcohol, opiates, narcotics and other addictive or habit forming substances, for central nervous disorders, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; implantable delivery systems comprised of a subcutaneous drug delivery device sold filled with sustainable release pharmaceutical preparations used in the treatment of addiction to and abuse of alcohol, opiates, narcotics and other addictive or habit forming substances, central nervous disorders and other serious and life-threatening diseases, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; pharmaceuticals, namely, implantable drug delivery system comprised of a subcutaneous drug delivery device sold filled with a polymer-based subdermal matrix formulation for the sustained release of drugs in the treatment of opiate addiction; pharmaceuticals, namely, implantable drug delivery system comprised of a subcutaneous drug delivery device sold filled with a polymer-based matrix formulation for the sustained release of drugs in the treatment of central nervous system disorders and other serious and life-threatening diseases
